Current News Today

- Advertisement -

- Advertisement -

Immunome stock more than triples after isolating antibodies in treatment of

Shares of Immunome Inc.

blasted 212.6% higher toward new highs Thursday, to pace all of the premarket gainers trading on major U.S. exchanges, after biopharmaceutical company said it has isolated potent antibodies that are capable of neutralizing several SARS-CoV-2 variants, including the South African Variant (B.1.351) in pseudovirus testing. Trading volume was about 506,600 shares, compared with the full-day average of about 117,600 shares. The company has been working to develop a cocktail of antibodies (IMM-BCP-001) that can act as a treatment for COVID-19. “Our findings underscore the power of Immunome’s discovery engine to quickly identify antibodies that are broadly effective against SARS-CoV-2 and its variants,” said Chief Executive Purnanand Sarma. “We are encouraged by these results and plan to continue development efforts on these antibodies.” The stock, which went public on Oct. 2, 2020, has run up 129.6% year to date through Wednesday, while the iShares Nasdaq Biotechnology ETF

has advanced 10.6% and the S&P 500

has gained 4.7%.

Read More:Immunome stock more than triples after isolating antibodies in treatment of

Get real time updates directly on you device, subscribe now.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.